Tools


Sitemap

Sitemap

Brain plaques in multiple sclerosis patients

Healthcare News | 2012-04-05

image
MAGNETOM 7T

In MAGNETOM 7T At the NeuroCure Clinical Research Center at Charité Medical University in Berlin, researchers used MAGNETOM 7 Tesla1 magnetic resonance imaging (MRI) system with an A T1-weighted magnetization-prepared rapid acquisition and multiple gradient-echo (MP-RAGE) protocol helps to clearly visualize cortical lesions in multiple sclerosis (MS) patients.

From black holes…

T1-weighted sequences are used to differentiate irreversible brain tissue damage commonly called “black holes”. Black holes are associated with the progression of MS and cerebral atrophy. Spin-echo T1-weighted images show a proportion of T2 hyperintense lesions or black holes that appear hypointense to the surrounding normal-appearing white matter for an extended period of time. The study included 20 patients with relapsing-remitting MS from the outpatient clinics of the NeuroCure Clinical Research Center. There were 11 male and nine female patients with a mean age of 42 years and mean disease duration of 3.1 years. For comparison purposes, 14 healthy control subjects also were enrolled. All 34 subjects received brain scans using the 7 Tesla MAGNETOM MRI system from Siemens with a 24-channel head coil. In addition, a subgroup of 18 patients with MS received brain scans with a 1.5 Tesla system.

to clarity in imaging

The analysis found that the use of MPRAGE in 7T provided evidence for a total of 728 lesions, compared with 584 lesions with 7 Tesla FLASH and 399 lesions with conventional 1.5 Tesla MPRAGE. In addition, 7 Tesla T2-weighted FLASH revealed 604 cerebral lesions in the patients with relapsing-remitting MS, with a mean of 30.2 lesions per patient. T1-weighted MPRAGE at 7 Tesla is highly sensitive in detecting multiple sclerosis plaques within white and gray brain matter, and the technique depicted structural damage in each lesion.

Contact Center

International (English): +49 69 797 6602
You can call us Monday through Friday
8 am to 5 pm CET

1 The product is still under development and not commercially available yet. Its future availability cannot be ensured.

Did this information help you?
Thank you for your response
We detected numbers and/or an '@' symbol in your comment. Are you trying to enter a phone number or email address so that we may contact you, please contact us via our email form instead.

Note: to get a direct personal response, please contact us via our email form.

Thank you